IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
Open accessThe DOI matches its Crossref record; 40 of the 50 references it cites were found in a registry or an index.
Abstract
The anti-tumor activity of recombinant mAb's directed against tumor cell growth receptors has generally been considered to result from direct antiproliferative effects, the induction of apoptosis, or possibly Ab-dependent cellular cytotoxicity mediated against tumor targets.However, it remains unclear to what degree these mechanisms actually aid in the clearance of Ab-coated tumor cells in vivo.We show here that NK cells secrete a distinct profile of potent immunostimulatory cytokines in response to dual stimulation with Ab-coated tumor cells and IL-12.This response could not be duplicated by costimulation with other ILs and was significantly enhanced in the presence of monocytes.Cytokine production was dependent upon synergistic signals mediated by the activating receptor for the Fc portion of IgG (FcγRIII) and the IL-12 receptor expressed on NK cells.Coadministration of Ab-coated tumor cells and IL-12 to BALB/c mice resulted in enhanced circulating levels of NK cell-derived cytokines with the capacity to augment anti-tumor immunity.These findings suggest that, in addition to mediating cellular cytotoxicity and apoptosis, the anti-tumor activity of mAb's might also result from activation of a potent cytokine secretion program within immune effectors capable of recognizing mAb-coated targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, increase in IL-12 levels might enhance the efficacy of immunotherapy by increasing the production of IFN-ɤ to stimulate the development and enhance the cytotoxicity of activated NK cells (100) and T cells and to accelerate the differentiation of CD4+ Th0 cells toward the Th1 phenotype, thus improving antibody-dependent cellular cytotoxicity (101).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [100]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
THE INTERLEUKIN-12/INTERLEUKIN-12-RECEPTOR SYSTEM: Role in Normal and Pathologic Immune Responses
Gately, M. K., Renzetti, L. M., Magram, J., Stern, A. S., Adorini, L., Gubler, U., & Presky, D. H. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.495 · Cited by 1,231
Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells
Thierfelder, W. E., van Deursen, J. M., Yamamoto, K., Tripp, R. A., Sarawar, S. R., Carson, R. T., Sangster, M. Y., Vignali, D. A. A., Doherty, P. C., Grosveld, G. C., et al. (1996) · Nature · doi:10.1038/382171a0 · Cited by 1,180
Carson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., Paxton, R., Anderson, D., Eisenmann, J., Grabstein, K., & Caligiuri, M. A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.4.1395 · Cited by 1,092
Self-citationPegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Ross, J. S., & Fletcher, J. A. (1998) · STEM CELLS · doi:10.1002/stem.160413 · Cited by 985
Biology and clinical relevance of human natural killer cells
Robertson, M., & Ritz, J. (1990) · Blood · doi:10.1182/blood.v76.12.2421.2421 · Cited by 931
ERBB2 oncogene in human breast cancer and its clinical significance
Révillion, F., Bonneterre, J., & Peyrat, J. P. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10157-5 · Cited by 448
Stress and Immune Responses After Surgical Treatment for Regional Breast Cancer
Andersen, B. L., Farrar, W. B., Golden-Kreutz, D., Kutz, L. A., MacCallum, R., Courtney, M. E., & Glaser, R. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.1.30 · Cited by 398
Oliver, J. M., Burg, D. L., Wilson, B. S., McLaughlin, J. L., & Geahlen, R. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)43936-1 · Cited by 338
IL-12 synergizes with IL-18 or IL-1β for IFN-γ production from human T cells
Tominaga, K., Yoshimoto, T., Torigoe, K., Kurimoto, M., Matsui, K., Hada, T., Okamura, H., & Nakanishi, K. (2000) · International Immunology · doi:10.1093/intimm/12.2.151 · Cited by 333
Bacterial DNA-Induced NK Cell IFN-γ Production Is Dependent on Macrophage Secretion of IL-12
Chace, J. H., Hooker, N. A., Mildenstein, K. L., Krieg, A. M., & Cowdery, J. S. (1997) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1997.4380 · Cited by 291
Hypomethylation of pericentromeric DNA in breast adenocarcinomas
Narayan, A., Ji, W., Zhang, X.-Y., Marrogi, A., Graff, J. R., Baylin, S. B., & Ehrlich, M. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980911)77:6<833::aid-ijc6>3.0.co;2-v · Cited by 266
Nanni, P., Nicoletti, G., De Giovanni, C., Landuzzi, L., Di Carlo, E., Cavallo, F., Pupa, S. M., Rossi, I., Colombo, M. P., Ricci, C., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.9.1195 · Cited by 230
Stancovski, I., Hurwitz, E., Leitner, O., Ullrich, A., Yarden, Y., & Sela, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8691 · Cited by 203
Cassatella, M. A., Anegón, I., Cuturi, M. C., Griskey, P., Trinchieri, G., & Perussia, B. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.2.549 · Cited by 203
Contribution of Natural Killer Cells to Inhibition of Angiogenesis by Interleukin-12
Yao, L., Sgadari, C., Furuke, K., Bloom, E. T., Teruya-Feldstein, J., & Tosato, G. (1999) · Blood · doi:10.1182/blood.v93.5.1612 · Cited by 201
Valone, F. H., Kaufman, P. A., Guyre, P. M., Lewis, L. D., Memoli, V, Deo, Y., Graziano, R., Fisher, J. L., Meyer, L., & Mrozek-Orlowski, M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2281 · Cited by 180
Shalaby, M. R., Shepard, H. M., Presta, L., Rodrigues, M. L., Beverley, P. C., Feldmann, M., & Carter, P. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.1.217 · Cited by 176
Liu, Y., El-Ashry, D., Chen, D., Ding, I. Y. F., & Kern, F. G. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00665783 · Cited by 163
Carson, W. E., Parihar, R., Lindemann, M. J., Personeni, N., Dierksheide, J., Meropol, N. J., Baselga, J., & Caligiuri, M. A. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(2001010)31:10<3016::aid-immu3016>3.0.co;2-j · Cited by 155
Self-citationCytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12
Tannenbaum, C. S., Wicker, N., Armstrong, D., Tubbs, R., Finke, J., Bukowski, R. M., & Hamilton, T. A. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.2.693 · Cited by 155
Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G
Gobin, S. J. P., & van den Elsen, P. J. (2000) · Human Immunology · doi:10.1016/s0198-8859(00)00198-1 · Cited by 152
Aste-Amezaga, M., D'Andrea, A., Kubin, M., & Trinchieri, G. (1994) · Cellular Immunology · doi:10.1006/cimm.1994.1192 · Cited by 136
Receptor-induced death in human natural killer cells: involvement of CD16.
Ortaldo, J. R., Mason, A. T., & O'Shea, J. J. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.1.339 · Cited by 134
Skok, J., Poudrier, J., & Gray, D. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.8.4284 · Cited by 111
Rituximab: A New Therapeutic Monoclonal Antibody for Non‐Hodgkin's Lymphoma
Scott, S. D. (1998) · Cancer Practice · doi:10.1046/j.1523-5394.1998.006003195.x · Cited by 105
Ting, A. T., Dick, C. J., Schoon, R. A., Karnitz, L. M., Abraham, R. T., & Leibson, P. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.27.16415 · Cited by 99
Walker, W., Aste-Amézaga, M., Kastelein, R. A., Trinchieri, G., & Hunter, C. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5894 · Cited by 93
Dela Cruz, J. S., Trinh, K. R., Morrison, S. L., & Penichet, M. L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.9.5112 · Cited by 84
Prévost-Blondel, A., Roth, E., Rosenthal, F. M., & Pircher, H. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.7.3645 · Cited by 80
Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients
Haicheur, N., Escudier, B., Dorval, T., Negrier, S., De Mulder, P. H. M., Dupuy, J. M., Novick, D., Guillot, T., Wolf, S., Pouillart, P., et al. (2002) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.2000.01112.x · Cited by 78
Bonnema, J. D., Rivlin, K., Ting, A. T., Schoon, R. A., Abraham, R. T., & Leibson, P. J. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.5.2098 · Cited by 77
Chen, Y., Emtage, P. C. R., Zhu, Q., Foley, R., Muller, W. J., Hitt, M., Gauldie, J., & Wan, Y. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301396 · Cited by 76
Jones, R. G. A., & Landon, J. (2002) · Journal of Immunological Methods · doi:10.1016/s0022-1759(02)00031-5 · Cited by 75
Amakata, Y., Fujiyama, Y., Andoh, A., Hodohara, K., & Bamba, T. (2001) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2001.01550.x · Cited by 55
Lieberman, M. D., Sigal, R. K., Williams, N. N., & Daly, J. M. (1991) · Journal of Surgical Research · doi:10.1016/0022-4804(91)90211-4 · Cited by 42
Pignata, C., Prasad, K. V. S., Hallek, M. J., Druker, B. J., Rudd, C. E., Robertson, M. J., & Ritz, J. (1995) · Cellular Immunology · doi:10.1006/cimm.1995.1207 · Cited by 36
Yoshida, A., Takahashi, H. K., Nishibori, M., Iwagaki, H., Yoshino, T., Morichika, T., Yokoyama, M., Kondo, E., Akagi, T., & Tanaka, N. (2001) · Cellular Immunology · doi:10.1006/cimm.2001.1811 · Cited by 36
Effects of c-erbB2 Overexpression on the Drug Sensitivities of Normal Human Mammary Epithelial Cells
Orr, M. S., O'Connor, P. M., & Kohn, K. W. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.12.987 · Cited by 35
Rodríguez-Calvillo, M., Duarte, M. C., Tirapu, I., Berraondo, P., Mazzolini, G. D., Qian, C., Prìeto, J., & Melero, I. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(01)00792-5 · Cited by 33
van Ojik, H. H., Repp, R., Groenewegen, G., Valerius, T., & van de Winkel, J. G. J. (1997) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050434 · Cited by 30
Şahin, U., Kraft-Bauer, S., Ohnesorge, S., Pfreundschuh, M., & Renner, C. (1996) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050245 · Cited by 25
Costimulation of T-cell proliferation by a chimeric B7-antibody fusion protein
Gerstmayer, B., Hoffmann, M. K., Altenschmidt, U., & Wels, W. S. (1997) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050421 · Cited by 19
Divergent Phosphotyrosine Signaling via FcγRIIIA on Human NK Cells
Manciulea, M., Rabinowich, H., Sulica, A., Lin, W., Whiteside, T. L., DeLeo, A. B., Herberman, R. B., & Corey, S. J. (1996) · Cellular Immunology · doi:10.1006/cimm.1996.0008 · Cited by 18
Synergistic anti-tumor effects with co-expression of GM-CSF and IFN-γ in murine tumors
Yoon, S. J., Heo, D. S., Kang, J. O., Lee, S. G., Kim, C. D., Sung, M., & Kim, N. K. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980911)77:6<907::aid-ijc18>3.0.co;2-y · Cited by 16
The mechanism of activation of NK-cell IFN-γ production by ligation of CD28
Cheung, J. C., Koh, C. Y., Gordon, B. E., Wilder, J. A., & Yuan, D. (1999) · Molecular Immunology · doi:10.1016/s0161-5890(99)00051-6 · Cited by 15
Research works printed but not linked: 10
- Sarup, J.C., et al. 1991. Characterization of an anti-p185HER2 mono- clonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul. 1:72-82.
- Baselga, J., and Albanell, J. 2001. Mechanisms of action of anti-HER2 monoclonal antibodies. Ann. Oncol. 12:S35-S41. · doi:10.1023/a:1011163824080
- Sliwkowski, M.X., et al. 1999. Nonclinical studies addressing the mech- anism of action of trastuzumab (Herceptin). Semin. Oncol. 26:60-70.
- Penichet, M.L., et al. 1999. In vivo properties of three human HER2/neu- expressing murine cell lines in immunocompetent mice. Lab. Anim. Sci. 49:179-188.
- Fleming, G.F., et al. 1999. A phase I CALGB trial of recombinant human anti-HER2 monoclonal antibody plus low-dose interleukin2 in solid tumors. Proc. Am. Soc. Clin. Oncol. 18:184a. (Abstr. 710)
- Weiner, L.M., et al. 1995. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res. 55:4586-4593.
- Penichet, M.L., Dela Cruz, J.S., Shin, S.U., and Morrison, S.L. 2001. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Hum. Antibodies. 10:43-49. · doi:10.3233/hab-2000-10107
- Peng, L.S., Penichet, M.L., and Morrison, S.L. 1999. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J. Immunol. 163:250-258. · doi:10.4049/jimmunol.163.1.250
- Cavallo, F., et al. 1999. Immune events associated with the cure of estab- lished tumors and spontaneous metastases by local and systemic inter- leukin-12. Cancer Res. 59:414-421.
- Parihar, R. et al. 2001. A phase I trial of Herceptin and interleukin-12 in patients with HER2-overexpressing malignancies. Proc. Am. Soc. Clin. Oncol. 20:258a. (Abstr. 1031)
Cited by
Caligiuri, M. A. (2008) · Blood · doi:10.1182/blood-2007-09-077438 · Cited by 1,905
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
NK cell-based immunotherapy for malignant diseases
Cheng, M., Chen, Y., Xiao, W., Sun, R., & Tian, Z. (2013) · Cellular & Molecular Immunology · doi:10.1038/cmi.2013.10 · Cited by 631
Human natural killer cell development and biology
Farag, S. S., & Caligiuri, M. A. (2006) · Blood Reviews · doi:10.1016/j.blre.2005.10.001 · Cited by 506
Interleukin 12: still a promising candidate for tumor immunotherapy?
Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1523-1 · Cited by 495
Metadata
- Authors
- Parihar, R., Dierksheide, J., Hu, Y., & Carson, W. E.
- Affiliations
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- The Ohio State University (US)
- Corresponding author
- Carson, William E.
- Venue
- Journal of Clinical Investigation
- Published
- 2002-10-01
- Volume
- 110
- Issue
- 7
- Pages
- 983-992
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W4237052860
- Cited by
- 23
- References
- 40
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 4 · 2022: 1 · 2020: 2 · 2019: 2 · 2018: 2 · 2015: 2 · 2014: 1 · 2013: 1
- FWCI
- 0.11
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Funders
- Ohio State University
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- IL-12, natural killer cells, monoclonal antibodies, antitumor immunity, FcγRIII, IL-12 receptor, monocytes, antibody-dependent cellular cytotoxicity, anti-idiotypic antibodies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.